| abstract |
The disclosure is directed to a device and method of treating bone formation disorders or conditions by bioengineering a targeted bone tissue and modulating the homeostasis of osteogenesis and bone resorption by a localized delivery of peripheral blood mononuclear cells and/or hematopoietic stem cells, and/or cells, such as osteoclasts, obtained by the ex vivo differentiation of these cells. A therapeutic strategy, as well as a device to deliver the therapeutic strategy, is described herein. |